The Endocannabinoid System: Role in Energy Regulation

Pediatric Blood and Cancer

Volumn 58, Issue 1, 2012, Pages 144-148

  Gamage, Thomas F ^a   Lichtman, Aron H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Anandamide; Appetite; Endogenous cannabinoid; Lipogenesis; Obesity; Rimonabant

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADIPOCYTE; ADVANCED CANCER; ANTIEMETIC ACTIVITY; APPETITE; BIOSYNTHESIS; CACHEXIA; CALORIC INTAKE; CANCER CHEMOTHERAPY; DRUG TARGETING; EATING DISORDER; ENERGY BALANCE; EPITHELIUM CELL; FEEDING BEHAVIOR; FEEDING DISORDER; FOOD INTAKE; GASTROINTESTINAL TRACT; HUMAN; HUNGER; HYPOTHALAMUS; IMMUNOCOMPETENT CELL; LIPOGENESIS; LIVER; LOW DRUG DOSE; MICROGLIA; MYENTERIC PLEXUS; NAUSEA AND VOMITING; NODOSE GANGLION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; VAGUS NERVE; WEIGHT GAIN;

ENDOCANNABINOIDS; ENERGY METABOLISM; HUMANS;

EID: 81155125290     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23367     Document Type: Review

References (84)

1. Mechoulam R. Cannabinoids as therapeutics. Basel, Boston: Birkhäuser; 2005. x, 272 pp.
2. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-1647.
3. Elsohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 2005;78:539-548.
4. Schwartzberg L. Chemotherapy-induced nausea and vomiting: Clinician and patient perspectives. J Support Oncol 2007;5:5-12.
5. Slatkin N. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: Beyond prevention of acute emesis. J Support Oncol 2007;5:1-9.
6. Van Gaal L, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008;31:S229-S240.
7. Matsuda L, Lolait S, Brownstein M, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
8. Munro S, Thomas K, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. 1993.
9. Howlett A. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995;35:607-634.
10. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462.
11. Pertwee R. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397-411.
12. Pertwee R. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci 1999;65:597-605.
13. Herkenham M, Lynn A, Johnson M, et al. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991;11:563.
14. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
15. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoyglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
16. Devane W, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946.
17. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008;108:1687-1707.
18. Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. 1994.
19. Kano M, Ohno-Shosaku T, Hashimotodani Y, et al. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009;89:309.
20. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997;388:773-778.
21. Gao Y, Vasilyev DV, Goncalves MB, et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 2010;30:2017-2024.
22. Min R, Testa-Silva G, Heistek TS, et al. Diacylglycerol lipase is not involved in depolarization-induced suppression of inhibition at unitary inhibitory connections in mouse hippocampus. J Neurosci 2010;30:2710-2715.
23. Wang J, Okamoto Y, Tsuboi K, et al. The stimulatory effect of phosphatidylethanolamine on N-acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD). Neuropharmacology 2008;54:8-15.
24. Leung D, Saghatelian A, Simon G, et al. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006;45:4720-4726.
25. Muccioli G. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 2010.
26. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem 2006;281:26465-26472.
27. Simon GM, Cravatt BF. Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol Biosyst 2010;6:1411-1418.
28. Beltramo M, Stella N, Calignano A, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997;277:1094-1097.
29. Piomelli D, Beltramo M, Glasnapp S, et al. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA 1999;96:5802-5807.
30. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001;98:9371-9376.
31. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002;99:10819-10824.
32. Blankman J, Simon G, Cravatt B. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007;14:1347-1356.
33. Marrs W, Blankman J, Horne E, et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 2010;13:951-957.
34. Matias I, Di Marzo V. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Invest 2006;29:15.
35. Mechoulam R, Berry E, Avraham Y, et al. Endocannabinoids, feeding and suckling-From our perspective. Int J Obes 2006;30:S24-S28.
36. Hollister LE. Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. Clin Pharmacol Ther 1971;12:44-49.
37. Abel E. Effects of marihuana on the solution of anagrams, memory and appetite. Nature 1971;231:260-261.
38. Harrold J, Williams G. The cannabinoid system: A role in both the homeostatic and hedonic control of eating? Br J Nutr 2007;90:729-734.
39. Greenberg I, Kuehnle J, Mendelson J, et al. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology 1976;49:79-84.
40. Foltin R, Brady J, Fischman M. Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 1986;25:577-582.
41. Di Marzo V, Ligresti A, Cristino L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes 2009;33:S18-S24.
42. Machado R, Stéfano S, De Cássia H, et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: Systematic review and meta-analysis. Eur J Cancer Care 2008;17:431.
43. 9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. The pharmacology of marihuana. 1976; pp 763-776.
44. Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:913-919.
45. Plasse T, Gorter R, Krasnow S, et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991;40:695-700.
46. Sofia R, Knobloch L. Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats. Pharmacol Biochem Behav 1976;4:591-599.
47. Glick S, Milloy S. Increased and decreased eating following THC administration. Psychon Sci 1972;29:6.
48. Brown J, Kassouny M, Cross J. Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of [Delta] 9-tetrahydrocannabinol1. Behavioral biology 1977;20:104-110.
49. Drewnowski A, Grinker J. Food and water intake, meal patterns and activity of obese and lean Zucker rats following chronic and acute treatment with delta9-tetrahydrocannabinol. Pharmacol biochem behav 1978;9:619.
50. Wiley JL, Burston JJ, Leggett DC, et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005;145:293-300.
51. McLaughlin C, Baile C, Bender P. Cannabinols and feeding in sheep. Psychopharmacology 1979;64:321-323.
52. Vaupel D, Morton E. Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens. Pharmacol Biochem Behav 1982;17:539-545.
53. Hao S, Avraham Y, Mechoulam R, et al. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000;392:147-156.
54. Williams CM, Kirkham TC. Observational analysis of feeding induced by Delta9-THC and anandamide. Physiol Behav 2002;76:241-250.
55. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612.
56. Williams C, Kirkham T. Anandamide induces overeating: Mediation by central cannabinoid (CB1) receptors. Psychopharmacology 1999;143:315-317.
57. Arnone M, Maruani J, Chaperon F, et al. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997;132:104-106.
58. Trojniar W, Wise R. Facilitory effect of 9-tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology 1991;103:172-176.
59. Jamshidi N, Taylor D. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001;134:1151-1154.
60. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825.
61. Kirkham T, Williams C, Fezza F, et al. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002;136:550-557.
62. Shinohara Y, Inui T, Yamamoto T, et al. Cannabinoid in the nucleus accumbens enhances the intake of palatable solution. Neuroreport 2009;20:1382.
63. Kirkham T, Williams C. The cannabinoid receptor antagonist SR141716 fails to suppress sucrose sham feeding. J Psychopharmacol 1998:12.
64. DiPatrizio N, Simansky K. Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 2008;28:9702.
65. Yoshida R, Ohkuri T, Jyotaki M, et al. Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci USA 2010;107:935.
66. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-431.
67. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305.
68. Simiand J, Keane M, Keane P, et al. SR141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998;9:179.
69. Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998;63:PL113-117.
70. Freedland C, Poston J, Porrino L. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 2000;67:265-270.
71. Ward S, Dykstra L. The role of CB1 receptors in sweet versus fat reinforcement: Effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 2005;16:381.
72. Thornton-Jones Z, Vickers S, Clifton P. The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology 2005;179:452-460.
73. Verty A, Singh M, McGregor I, et al. The cannabinoid receptor antagonist SR141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology 2003;168:314-323.
74. Pietras T, Rowland N. Effect of opioid and cannabinoid receptor antagonism on orphanin FQ-induced hyperphagia in rats. Eur J Pharmacol 2002;442:237-239.
75. Kirkham T, Williams C. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacologia 2001;153:267-270.
76. Verty A, McFarlane J, McGregor I, et al. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 2004;145:3224.
77. Verty A, McFarlane J, McGregor I, et al. Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology 2004;47:593-5603.
78. Pavon F, Bilbao A, Hernández-Folgado L, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-3-hexyl-1H-1, 2, 4-triazole-LH 21. Neuropharmacology 2006;51:358-366.
79. Fernandez J, Allison D. Rimonabant Sanofi-Synthélabo. Curr Opin Invest Drugs (London, England: 2000) 2004;5:430.
80. Pi-Sunyer F, Aronne L, Heshmati H, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 2006;295:761.
81. Wadden TA, Fujioka K, Toubro S, et al. A Randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. Obesity (Silver Spring) 2010.
82. Martin-Garcia E, Burokas A, Martin M, et al. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. J Neurochem 2010;112:1338-1351.
83. Randall PA, Vemuri VK, Segovia KN, et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav 2010.
84. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120:2953-2966.